Results 21 to 30 of about 20,614 (289)
Hospital Pharmacy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +2 more sources
Frontiers in Cardiovascular Medicine, 2021 Objectives: Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy.
Christof Burgdorf +4 more
doaj +1 more source
"Primum non nocere (First, do no harm)". Case report
Кардиоваскулярная терапия и профилактика, 2023 Diastolic myocardial dysfunction is the most important pathogenetic factor in heart failure and makes a significant contribution to hemodynamic disorders, which leads to a significant deterioration in the quality of life and prognosis of patients.
D. A. Nefedova +2 more
doaj +1 more source
Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
Frontiers in Pharmacology, 2022 Cardiovascular diseases have become a major clinical burden globally. Heart failure is one of the diseases that commonly emanates from progressive uncontrolled hypertension. This gives rise to the need for a new treatment for the disease.
Nor Hidayah Mustafa +5 more
doaj +1 more source
Archives of Pharmaceutical Sciences Ain Shams University, 2023 One of the leading causes of illness and mortality worldwide is cardiovascular disease. The optimum therapy in the majority of cases is accomplished by combining a number of medications, each of which has a unique mechanism of action, to treat ...
Ragaa Magdy +3 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Background: The episode of acute decompensated heart failure (ADHF) is the main cause of hospitalization for heart failure (HF). Sacubitril–valsartan has been proven to be effective in reducing the risks of hospitalization for HF in ADHF.
Tianyang Hu, Yiting Liu, Yake Lou
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF).
April F. Mohanty +14 more
doaj +1 more source
European Heart Journal, 2023 Aims The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but ...
M. Vaduganathan +16 more
semanticscholar +1 more source
Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure [PDF]
, 2018 Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Claggett, Brian +14 more
core +9 more sources